Table 1 General characteristics of studies included in meta-analysis
References | Time | Study design | Country | Sample size | Mean age (year) | Gender, M/F | Diagnostic criteria | Experiment group | Control group | AHQR/NOS (stars/ scores) |
|---|---|---|---|---|---|---|---|---|---|---|
Buyukkaya E [9] | 2014 | Case-control | Turkey | 141 | 47.5 ± 11.7 | 76/65 | NCEP-ATP3 | MS | Non-MS | 8/9 |
Surendar J [10] | 2016 | Cross-sectional | India | 754 | 48.2 ± 12.2 | 420/334 | NCEP-ATP3 | MS | Non-MS | 10/11 |
Battaglia S [11] | 2020 | Cross-sectional | Italy | 771 | 56.34 ± 13.63 | 391/380 | IDF | MS | Non-MS | 11/11 |
Kaya T [12] | 2017 | Cross-sectional | Turkey | 261 | 56.7 ± 10.5 | 113/148 | NCEP-ATP3 | MS | Non-MS | 11/11 |
Kim JH [13] | 2017 | Cross-sectional | Korea | 1,007 | 48.3 ± 9.7 | 659/348 | NCEP-ATP3 | MS | Non-MS | 10/11 |
Liu CC [14] | 2019 | Retrospective cohort | Tai Wan | 34,013 | 50.46 ± 11.09 | 23,877/10,136 | NCEP-ATP3 | MS | Non-MS | 7/9 |
Tang K [15] | 2017 | Retrospective cohort | China | 513 | 52.27 ± 10.95 | 294/219 | NCEP-ATP3 | MS | Non-MS | 7/9 |
Wang PB [16] | 2022 | Cross-sectional | China | 7,420 | 53.71 ± 8.68 | 3,359/4,061 | IDF | MS | Non-MS | 10/11 |
Yasar Z [17] | 2015 | Case-control | Turkey | 140 | 65.16 ± 10.3 | 103/37 | IDF | MS | Non-MS | 8/9 |
Zubiaga L [18] | 2020 | Retrospective cohort | Spain | 200 | 43.9 ± 10.9 | 150/50 | NCEP-ATP3 | MS | Non-MS | 8/9 |
Li N [19] | 2023 | Cross-sectional | China | 7,726 | 48.40 ± 10.73 | 4,397/3,329 | Chinese Diabetes Society criteria | MS | Non-MS | 10/11 |
Mohan M [20] | 2021 | Cross-sectional | India | 210 | 57 ± 9.545 | 108/102 | NCEP-ATP3 | MS | Non-MS | 10/11 |
Bahadir A [21] | 2015 | Cross-sectional | Turkey | 1,267 | 37.7 ± 10.8 | 109/1,068 | NCEP-ATP3 | MS | Non-MS | 11/11 |
Najafzadeh MJ [22] | 2023 | Cross-sectional | Iran | 1,033 | 45.16 ± 13.88 | 373/660 | NCEP-ATP3 | MS | Non-MS | 10/11 |
Omrani-Nava V [23] | 2023 | Retrospective cohort | Iran | 1,930 | 35–70 | 842/1,088 | NCEP-ATP3 | MS | Non-MS | 8/9 |
Ustuntas G [24] | 2021 | Case-control | Turkey | 219 | 70.5 ± 5.4 | 155/64 | NCEP-ATP3 | MS | Non-MS | 8/9 |
Al-Sarraf IAK [25] | 2018 | cross-sectional | Jordan | 87 | 42.7 ± 1.9 | 41/46 | IDF | MS | Non-MS | 10/11 |
AbuZayed R [26] | 2019 | Cross-sectional | Jordan | 88 | 49.86 ± 11.34 | 24/64 | IDF | MS | Non-MS | 10/11 |
Horan AA [27] | 2019 | Cross-sectional | Jordan | 88 | 49.78 ± 10.22 | 24/64 | IDF | MS | Non-MS | 10/11 |
Mauss D [28] | 2021 | Retrospective cohort | Germany | 689 | 45.5 ± 9.8 | 620/69 | AHA/NHLBI 2009 | MS | Non-MS | 7/9 |
Song PY [29] | 2022 | Cross-sectional | China | 860 | 61.45 ± 12.5 | 524/336 | IDF | MS | Non-MS | 10/11 |
Abdel-Moneim A [33] | 2019 | Case-control | Egypt | 250 | 44.08 ± 8.41 | 125/125 | NCEP-ATP3 | MS | Non-MS | 8/9 |
Lin HY [34] | 2021 | Retrospective cohort | China | 1,542 | 44.8 ± 12.6 | 1,056/486 | Chinese Diabetes Society criteria | High NLR | Low NLR | 9/9 |
Fang Q [35] | 2018 | Case-control | China | 3,080 | 50.75 ± 10.36 | 0/3,080 | AHA/NHLBI 2005 | High NLR | Low NLR | 8/9 |
Conteduca V [36] | 2018 | Retrospective cohort | Italy | 336 | 75 | 336/0 | NCEP-ATP3 | High NLR | Low NLR | 9/9 |
Meng G [37] | 2017 | Cross-sectional | China | 6,312 | 60.28 | 3,821/2,491 | AHA/NHLBI 2009 | High NLR | Low NLR | 10/11 |